EC Number |
Inhibitors |
Structure |
---|
6.3.5.1 | 3-[([7-[5-(benzyloxy)-2-(methoxycarbonyl)-1H-indol-1-yl]heptyl]oxy)carbonyl]-1-methylpyridinium |
- |
|
6.3.5.1 | 4-[([7-[5-(benzyloxy)-2-(methoxycarbonyl)-1H-indol-1-yl]heptyl]oxy)carbonyl]-N,N,N-trimethylanilinium |
- |
|
6.3.5.1 | 4-[([8-[5-(benzyloxy)-1H-indol-1-yl]octyl]oxy)carbonyl]-N,N,N-trimethylanilinium |
- |
|
6.3.5.1 | 4-[2-([9-[5-(benzyloxy)-2-(methoxycarbonyl)-1H-indol-1-yl]nonyl]oxy)-2-oxoethyl]-N,N,N-trimethylanilinium |
- |
|
6.3.5.1 | 6-diazo-5-oxo-L-norleucine |
- |
|
6.3.5.1 | adenosine 5'-[alpha,beta-methylene]triphosphate |
i.e. AMP-CPP, nonhydrolysable analogue of ATP |
|
6.3.5.1 | azaserine |
progressively inhibits glutamine-dependent activity. With NH4+ as amide donor there is an initial 20% inhibition, then the NH4+-dependent activity remains constant |
|
6.3.5.1 | diisopropyl fluorophosphate |
- |
|
6.3.5.1 | gossypol |
- |
|
6.3.5.1 | Mg2+ |
in excess of ATP |
|